<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39409149</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>19</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>09</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Advancements in the Development of Anti-SARS-CoV-2 Therapeutics.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">10820</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms251910820</ELocationID><Abstract><AbstractText>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes COVID-19, and so far, it has occurred five noteworthy variants of concern (VOC). SARS-CoV-2 invades cells by contacting its Spike (S) protein to its receptor on the host cell, angiotensin-converting enzyme 2 (ACE2). However, the high frequency of mutations in the S protein has limited the effectiveness of existing drugs against SARS-CoV-2 variants, particularly the Omicron variant. Therefore, it is critical to develop drugs that have highly effective antiviral activity against both SARS-CoV-2 and its variants in the future. This review provides an overview of the mechanism of SARS-CoV-2 infection and the current progress on anti-SARS-CoV-2 drugs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Junjie</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-4104-1082</Identifier><AffiliationInfo><Affiliation>Institute of Modern Fermentation Engineering and Future Foods, School of Light Industry and Food Engineering, Guangxi University, No. 100, Daxuedong Road, Nanning 530004, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Qianqian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences and Institute of Materia Medica, Xinjiang University, Urumqi 830017, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Zhengding</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences and Institute of Materia Medica, Xinjiang University, Urumqi 830017, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Xiyao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute of Modern Fermentation Engineering and Future Foods, School of Light Industry and Food Engineering, Guangxi University, No. 100, Daxuedong Road, Nanning 530004, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>32301020</GrantID><Agency>National Natural Science Foundation of China</Agency><Country /></Grant><Grant><GrantID>2023JJB140003</GrantID><Agency>Natural Science Foundation of Guangxi Province</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="D000085962">Angiotensin-Converting Enzyme 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="C000705307">ACE2 protein, human</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000085962" MajorTopicYN="Y">Angiotensin-Converting Enzyme 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Omicron</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">drug development</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>1</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39409149</ArticleId><ArticleId IdType="pmc">PMC11477007</ArticleId><ArticleId IdType="doi">10.3390/ijms251910820</ArticleId><ArticleId IdType="pii">ijms251910820</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W., Tian J.-H., Pei Y.-Y., et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265–269. doi: 10.1038/s41586-020-2008-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2008-3</ArticleId><ArticleId IdType="pmc">PMC7094943</ArticleId><ArticleId IdType="pubmed">32015508</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., Wang B., Xiang H., Cheng Z., Xiong Y., et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323:1061–1069. doi: 10.1001/jama.2020.1585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.1585</ArticleId><ArticleId IdType="pmc">PMC7042881</ArticleId><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu R., Zhao X., Li J., Niu P., Yang B., Wu H., Wang W., Song H., Huang B., Zhu N., et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet. 2020;395:565–574. doi: 10.1016/S0140-6736(20)30251-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30251-8</ArticleId><ArticleId IdType="pmc">PMC7159086</ArticleId><ArticleId IdType="pubmed">32007145</ArticleId></ArticleIdList></Reference><Reference><Citation>Walls A.C., Park Y.J., Tortorici M.A., Wall A., McGuire A.T., Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181:281–292.e286. doi: 10.1016/j.cell.2020.02.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.058</ArticleId><ArticleId IdType="pmc">PMC7102599</ArticleId><ArticleId IdType="pubmed">32155444</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi J.Y., Smith D.M. SARS-CoV-2 Variants of Concern. Yonsei Med. J. 2021;62:961–968. doi: 10.3349/ymj.2021.62.11.961.</Citation><ArticleIdList><ArticleId IdType="doi">10.3349/ymj.2021.62.11.961</ArticleId><ArticleId IdType="pmc">PMC8542474</ArticleId><ArticleId IdType="pubmed">34672129</ArticleId></ArticleIdList></Reference><Reference><Citation>Chenchula S., Karunakaran P., Sharma S., Chavan M. Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: A systematic review. J. Med. Virol. 2022;94:2969–2976. doi: 10.1002/jmv.27697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27697</ArticleId><ArticleId IdType="pmc">PMC9088621</ArticleId><ArticleId IdType="pubmed">35246846</ArticleId></ArticleIdList></Reference><Reference><Citation>Arya R., Kumari S., Pandey B., Mistry H., Bihani S.C., Das A., Prashar V., Gupta G.D., Panicker L., Kumar M. Structural insights into SARS-CoV-2 proteins. J. Mol. Biol. 2021;433:166725. doi: 10.1016/j.jmb.2020.11.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2020.11.024</ArticleId><ArticleId IdType="pmc">PMC7685130</ArticleId><ArticleId IdType="pubmed">33245961</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M.Y., Zhao R., Gao L.J., Gao X.F., Wang D.P., Cao J.M. SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development. Front. Cell Infect. Microbiol. 2020;10:587269. doi: 10.3389/fcimb.2020.587269.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2020.587269</ArticleId><ArticleId IdType="pmc">PMC7723891</ArticleId><ArticleId IdType="pubmed">33324574</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuriakose J., Montezano A.C., Touyz R.M. ACE2/Ang-(1-7)/Mas1 axis and the vascular system: Vasoprotection to COVID-19-associated vascular disease. Clin. Sci. 2021;135:387–407. doi: 10.1042/CS20200480.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/CS20200480</ArticleId><ArticleId IdType="pmc">PMC7846970</ArticleId><ArticleId IdType="pubmed">33511992</ArticleId></ArticleIdList></Reference><Reference><Citation>Sodhi C.P., Nguyen J., Yamaguchi Y., Werts A.D., Lu P., Ladd M.R., Fulton W.B., Kovler M.L., Wang S., Prindle T., Jr., et al. A Dynamic Variation of Pulmonary ACE2 Is Required to Modulate Neutrophilic Inflammation in Response to Pseudomonas aeruginosa Lung Infection in Mice. J. Immunol. 2019;203:3000–3012. doi: 10.4049/jimmunol.1900579.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1900579</ArticleId><ArticleId IdType="pmc">PMC7458157</ArticleId><ArticleId IdType="pubmed">31645418</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Q., Chen R., Wu L., Huang Q., Wang X.X., Tian Y.Y., Zhang Y.D. Angiotensin-(1-7) reduces α-synuclein aggregation by enhancing autophagic activity in Parkinson’s disease. Neural Regen. Res. 2022;17:1138–1145. doi: 10.4103/1673-5374.324854.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.324854</ArticleId><ArticleId IdType="pmc">PMC8552854</ArticleId><ArticleId IdType="pubmed">34558543</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamming I., Timens W., Bulthuis M.L., Lely A.T., Navis G., van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 2004;203:631–637. doi: 10.1002/path.1570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.1570</ArticleId><ArticleId IdType="pmc">PMC7167720</ArticleId><ArticleId IdType="pubmed">15141377</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan J., Ge J., Yu J., Shan S., Zhou H., Fan S., Zhang Q., Shi X., Wang Q., Zhang L., et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581:215–220. doi: 10.1038/s41586-020-2180-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2180-5</ArticleId><ArticleId IdType="pubmed">32225176</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang J., Ye G., Shi K., Wan Y., Luo C., Aihara H., Geng Q., Auerbach A., Li F. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581:221–224. doi: 10.1038/s41586-020-2179-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2179-y</ArticleId><ArticleId IdType="pmc">PMC7328981</ArticleId><ArticleId IdType="pubmed">32225175</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambers J.P., Yu J., Valdes J.J., Arulanandam B.P. SARS-CoV-2, Early Entry Events. J. Pathog. 2020;2020:9238696. doi: 10.1155/2020/9238696.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/9238696</ArticleId><ArticleId IdType="pmc">PMC7707962</ArticleId><ArticleId IdType="pubmed">33299610</ArticleId></ArticleIdList></Reference><Reference><Citation>Wrapp D., Wang N., Corbett K.S., Goldsmith J.A., Hsieh C.L., Abiona O., Graham B.S., McLellan J.S. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260–1263. doi: 10.1126/science.abb2507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb2507</ArticleId><ArticleId IdType="pmc">PMC7164637</ArticleId><ArticleId IdType="pubmed">32075877</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson C.B., Farzan M., Chen B., Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol. 2022;23:3–20. doi: 10.1038/s41580-021-00418-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-021-00418-x</ArticleId><ArticleId IdType="pmc">PMC8491763</ArticleId><ArticleId IdType="pubmed">34611326</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M., Kleine-Weber H., Schroeder S., Krüger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A., et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181:271–280.e278. doi: 10.1016/j.cell.2020.02.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Liu Q., Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J. Med. Virol. 2020;92:418–423. doi: 10.1002/jmv.25681.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25681</ArticleId><ArticleId IdType="pmc">PMC7167049</ArticleId><ArticleId IdType="pubmed">31967327</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravi V., Saxena S., Panda P.S. Basic virology of SARS-CoV 2. Indian J. Med. Microbiol. 2022;40:182–186. doi: 10.1016/j.ijmmb.2022.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijmmb.2022.02.005</ArticleId><ArticleId IdType="pmc">PMC8919811</ArticleId><ArticleId IdType="pubmed">35300895</ArticleId></ArticleIdList></Reference><Reference><Citation>Guest P.C., Kesharwani P., Butler A.E., Sahebkar A. The COVID-19 Pandemic: SARS-CoV-2 Structure, Infection, Transmission, Symptomology, and Variants of Concern. Adv. Exp. Med. Biol. 2023;1412:3–26. doi: 10.1007/978-3-031-28012-2_1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-031-28012-2_1</ArticleId><ArticleId IdType="pubmed">37378759</ArticleId></ArticleIdList></Reference><Reference><Citation>Francisco R.D.S., Jr., Benites L.F., Lamarca A.P., de Almeida L.G.P., Hansen A.W., Gularte J.S., Demoliner M., Gerber A.L., Guimarães A.P.d.C., Antunes A.K.E., et al. Pervasive transmission of E484K and emergence of VUI-NP13L with evidence of SARS-CoV-2 co-infection events by two different lineages in Rio Grande do Sul, Brazil. Virus Res. 2021;296:198345. doi: 10.1016/j.virusres.2021.198345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2021.198345</ArticleId><ArticleId IdType="pmc">PMC7898980</ArticleId><ArticleId IdType="pubmed">33631222</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Wu S., Wu B., Yang Q., Chen A., Li Y., Zhang Y., Pan T., Zhang H., He X. SARS-CoV-2 Omicron strain exhibits potent capabilities for immune evasion and viral entrance. Signal Transduct. Target. Ther. 2021;6:430. doi: 10.1038/s41392-021-00852-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00852-5</ArticleId><ArticleId IdType="pmc">PMC8678971</ArticleId><ArticleId IdType="pubmed">34921135</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y., Han J., Zhang Y., He J., Yu W., Zhang X., Wu J., Zhang S., Kong Y., Guo Y., et al. SARS-CoV-2 Omicron Variant: Epidemiological Features, Biological Characteristics, and Clinical Significance. Front. Immunol. 2022;13:877101. doi: 10.3389/fimmu.2022.877101.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.877101</ArticleId><ArticleId IdType="pmc">PMC9099228</ArticleId><ArticleId IdType="pubmed">35572518</ArticleId></ArticleIdList></Reference><Reference><Citation>Patone M., Thomas K., Hatch R., Tan P.S., Coupland C., Liao W., Mouncey P., Harrison D., Rowan K., Horby P., et al. Mortality and critical care unit admission associated with the SARS-CoV-2 lineage B.1.1.7 in England: An observational cohort study. Lancet Infect. Dis. 2021;21:1518–1528. doi: 10.1016/S1473-3099(21)00318-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00318-2</ArticleId><ArticleId IdType="pmc">PMC8219489</ArticleId><ArticleId IdType="pubmed">34171232</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies N.G., Jarvis C.I., Edmunds W.J., Jewell N.P., Diaz-Ordaz K., Keogh R.H. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature. 2021;593:270–274. doi: 10.1038/s41586-021-03426-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03426-1</ArticleId><ArticleId IdType="pmc">PMC9170116</ArticleId><ArticleId IdType="pubmed">33723411</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortega M.A., García-Montero C., Fraile-Martinez O., Colet P., Baizhaxynova A., Mukhtarova K., Alvarez-Mon M., Kanatova K., Asúnsolo A., Sarría-Santamera A. Recapping the Features of SARS-CoV-2 and Its Main Variants: Status and Future Paths. J. Pers. Med. 2022;12:995. doi: 10.3390/jpm12060995.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm12060995</ArticleId><ArticleId IdType="pmc">PMC9225183</ArticleId><ArticleId IdType="pubmed">35743779</ArticleId></ArticleIdList></Reference><Reference><Citation>Cegolon L., Magnano G., Negro C., Larese Filon F. SARS-CoV-2 Reinfections in Health-Care Workers, 1 March 2020-31 January 2023. Viruses. 2023;15:1551. doi: 10.3390/v15071551.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15071551</ArticleId><ArticleId IdType="pmc">PMC10384331</ArticleId><ArticleId IdType="pubmed">37515237</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue C., Song W., Wang L., Jian F., Chen X., Gao F., Shen Z., Wang Y., Wang X., Cao Y. ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5. Lancet Infect. Dis. 2023;23:278–280. doi: 10.1016/S1473-3099(23)00010-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00010-5</ArticleId><ArticleId IdType="pmc">PMC9897732</ArticleId><ArticleId IdType="pubmed">36746173</ArticleId></ArticleIdList></Reference><Reference><Citation>Uraki R., Ito M., Furusawa Y., Yamayoshi S., Iwatsuki-Horimoto K., Adachi E., Saito M., Koga M., Tsutsumi T., Yamamoto S., et al. Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB. Lancet Infect. Dis. 2023;23:30–32. doi: 10.1016/S1473-3099(22)00816-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00816-7</ArticleId><ArticleId IdType="pmc">PMC9729000</ArticleId><ArticleId IdType="pubmed">36495917</ArticleId></ArticleIdList></Reference><Reference><Citation>Volz E., Mishra S., Chand M., Barrett J.C., Johnson R., Geidelberg L., Hinsley W.R., Laydon D.J., Dabrera G., O’Toole Á., et al. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature. 2021;593:266–269. doi: 10.1038/s41586-021-03470-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03470-x</ArticleId><ArticleId IdType="pubmed">33767447</ArticleId></ArticleIdList></Reference><Reference><Citation>Galloway S.E., Paul P., MacCannell D.R., Johansson M.A., Brooks J.T., MacNeil A., Slayton R.B., Tong S., Silk B.J., Armstrong G.L., et al. Emergence of SARS-CoV-2 B.1.1.7 Lineage—United States, December 29, 2020-January 12, 2021. MMWR Morb. Mortal. Wkly. Rep. 2021;70:95–99. doi: 10.15585/mmwr.mm7003e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7003e2</ArticleId><ArticleId IdType="pmc">PMC7821772</ArticleId><ArticleId IdType="pubmed">33476315</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy K.R., Rennick L.J., Nambulli S., Robinson-McCarthy L.R., Bain W.G., Haidar G., Duprex W.P. Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape. Science. 2021;371:1139–1142. doi: 10.1126/science.abf6950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf6950</ArticleId><ArticleId IdType="pmc">PMC7971772</ArticleId><ArticleId IdType="pubmed">33536258</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemp S.A., Collier D.A., Datir R.P., Ferreira I., Gayed S., Jahun A., Hosmillo M., Rees-Spear C., Mlcochova P., Lumb I.U., et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature. 2021;592:277–282. doi: 10.1038/s41586-021-03291-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03291-y</ArticleId><ArticleId IdType="pmc">PMC7610568</ArticleId><ArticleId IdType="pubmed">33545711</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H., Zhang Q., Wei P., Chen Z., Aviszus K., Yang J., Downing W., Jiang C., Liang B., Reynoso L., et al. The basis of a more contagious 501Y.V1 variant of SARS-CoV-2. Cell Res. 2021;31:720–722. doi: 10.1038/s41422-021-00496-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-021-00496-8</ArticleId><ArticleId IdType="pmc">PMC8063779</ArticleId><ArticleId IdType="pubmed">33893398</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniloski Z., Jordan T.X., Ilmain J.K., Guo X., Bhabha G., tenOever B.R., Sanjana N.E. The Spike D614G mutation increases SARS-CoV-2 infection of multiple human cell types. eLife. 2021;10:e65365. doi: 10.7554/eLife.65365.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.65365</ArticleId><ArticleId IdType="pmc">PMC7891930</ArticleId><ArticleId IdType="pubmed">33570490</ArticleId></ArticleIdList></Reference><Reference><Citation>Weissman D., Alameh M.G., de Silva T., Collini P., Hornsby H., Brown R., LaBranche C.C., Edwards R.J., Sutherland L., Santra S., et al. D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization. Cell Host Microbe. 2021;29:23–31.e24. doi: 10.1016/j.chom.2020.11.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.11.012</ArticleId><ArticleId IdType="pmc">PMC7707640</ArticleId><ArticleId IdType="pubmed">33306985</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies N.G., Abbott S., Barnard R.C., Jarvis C.I., Kucharski A.J., Munday J.D., Pearson C.A.B., Russell T.W., Tully D.C., Washburne A.D., et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021;372:eabg3055. doi: 10.1126/science.abg3055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abg3055</ArticleId><ArticleId IdType="pmc">PMC8128288</ArticleId><ArticleId IdType="pubmed">33658326</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakur N., Gallo G., Newman J., Peacock T.P., Biasetti L., Hall C.N., Wright E., Barclay W., Bailey D. SARS-CoV-2 variants of concern alpha, beta, gamma and delta have extended ACE2 receptor host ranges. J. Gen. Virol. 2022;103:001735. doi: 10.1099/jgv.0.001735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.001735</ArticleId><ArticleId IdType="pubmed">35377298</ArticleId></ArticleIdList></Reference><Reference><Citation>Barton M.I., MacGowan S.A., Kutuzov M.A., Dushek O., Barton G.J., van der Merwe P.A. Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics. eLife. 2021;10:e70658. doi: 10.7554/eLife.70658.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.70658</ArticleId><ArticleId IdType="pmc">PMC8480977</ArticleId><ArticleId IdType="pubmed">34435953</ArticleId></ArticleIdList></Reference><Reference><Citation>Wibmer C.K., Ayres F., Hermanus T., Madzivhandila M., Kgagudi P., Oosthuysen B., Lambson B.E., de Oliveira T., Vermeulen M., van der Berg K., et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat. Med. 2021;27:622–625. doi: 10.1038/s41591-021-01285-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01285-x</ArticleId><ArticleId IdType="pubmed">33654292</ArticleId></ArticleIdList></Reference><Reference><Citation>Faria N.R., Mellan T.A., Whittaker C., Claro I.M., Candido D.D.S., Mishra S., Crispim M.A.E., Sales F.C.S., Hawryluk I., McCrone J.T., et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science. 2021;372:815–821. doi: 10.1126/science.abh2644.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abh2644</ArticleId><ArticleId IdType="pmc">PMC8139423</ArticleId><ArticleId IdType="pubmed">33853970</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman F.I., Ether S.A., Islam M.R. The “Delta Plus” COVID-19 variant has evolved to become the next potential variant of concern: Mutation history and measures of prevention. J. Basic Clin. Physiol. Pharmacol. 2022;33:109–112. doi: 10.1515/jbcpp-2021-0251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/jbcpp-2021-0251</ArticleId><ArticleId IdType="pubmed">34563102</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C., Ginn H.M., Dejnirattisai W., Supasa P., Wang B., Tuekprakhon A., Nutalai R., Zhou D., Mentzer A.J., Zhao Y., et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell. 2021;184:4220–4236.e4213. doi: 10.1016/j.cell.2021.06.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.06.020</ArticleId><ArticleId IdType="pmc">PMC8218332</ArticleId><ArticleId IdType="pubmed">34242578</ArticleId></ArticleIdList></Reference><Reference><Citation>Ao Z., Ouyang M.J., Olukitibi T.A., Yao X. SARS-CoV-2 Delta spike protein enhances the viral fusogenicity and inflammatory cytokine production. iScience. 2022;25:104759. doi: 10.1016/j.isci.2022.104759.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2022.104759</ArticleId><ArticleId IdType="pmc">PMC9281453</ArticleId><ArticleId IdType="pubmed">35854977</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Beltran W.F., Lam E.C., St Denis K., Nitido A.D., Garcia Z.H., Hauser B.M., Feldman J., Pavlovic M.N., Gregory D.J., Poznansky M.C., et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021;184:2372–2383.e2379. doi: 10.1016/j.cell.2021.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.03.013</ArticleId><ArticleId IdType="pmc">PMC7953441</ArticleId><ArticleId IdType="pubmed">33743213</ArticleId></ArticleIdList></Reference><Reference><Citation>Motozono C., Toyoda M., Zahradnik J., Saito A., Nasser H., Tan T.S., Ngare I., Kimura I., Uriu K., Kosugi Y., et al. SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity. Cell Host Microbe. 2021;29:1124–1136.e1111. doi: 10.1016/j.chom.2021.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.06.006</ArticleId><ArticleId IdType="pmc">PMC8205251</ArticleId><ArticleId IdType="pubmed">34171266</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y., Jian F., Wang J., Yu Y., Song W., Yisimayi A., Wang J., An R., Chen X., Zhang N., et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature. 2023;614:521–529. doi: 10.1038/s41586-022-05644-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05644-7</ArticleId><ArticleId IdType="pmc">PMC9931576</ArticleId><ArticleId IdType="pubmed">36535326</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeworowski L.M., Mühlemann B., Walper F., Schmidt M.L., Jansen J., Krumbholz A., Simon-Lorière E., Jones T.C., Corman V.M., Drosten C. Humoral immune escape by current SARS-CoV-2 variants BA.2.86 and JN.1, December 2023. Eurosurveillance. 2024;29:2300740. doi: 10.2807/1560-7917.ES.2024.29.2.2300740.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2024.29.2.2300740</ArticleId><ArticleId IdType="pmc">PMC10785204</ArticleId><ArticleId IdType="pubmed">38214083</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S., Yu Y., Xu Y., Jian F., Song W., Yisimayi A., Wang P., Wang J., Liu J., Yu L., et al. Fast evolution of SARS-CoV-2 BA.2·86 to JN.1 under heavy immune pressure. Lancet Infect. Dis. 2024;24:e70–e72. doi: 10.1016/S1473-3099(23)00744-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00744-2</ArticleId><ArticleId IdType="pubmed">38109919</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaku Y., Okumura K., Padilla-Blanco M., Kosugi Y., Uriu K., Hinay A.A., Jr., Chen L., Plianchaisuk A., Kobiyama K., Ishii K.J., et al. Virological characteristics of the SARS-CoV-2 JN.1 variant. Lancet Infect. Dis. 2024;24:e82. doi: 10.1016/S1473-3099(23)00813-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00813-7</ArticleId><ArticleId IdType="pubmed">38184005</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Pérez Marc G., Moreira E.D., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B., et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021;384:403–416. doi: 10.1056/NEJMoa2035389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews N., Stowe J., Kirsebom F., Toffa S., Rickeard T., Gallagher E., Gower C., Kall M., Groves N., O’Connell A.M., et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N. Engl. J. Med. 2022;386:1532–1546. doi: 10.1056/NEJMoa2119451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2119451</ArticleId><ArticleId IdType="pmc">PMC8908811</ArticleId><ArticleId IdType="pubmed">35249272</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D., Saunders N., Maes P., Guivel-Benhassine F., Planchais C., Buchrieser J., Bolland W.-H., Porrot F., Staropoli I., Lemoine F., et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022;602:671–675. doi: 10.1038/s41586-021-04389-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04389-z</ArticleId><ArticleId IdType="pubmed">35016199</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu L., Mok B.W.Y., Chen L.L., Chan J.M.C., Tsang O.T.Y., Lam B.H.S., Chuang V.W.M., Chu A.W.H., Chan W.M., Ip J.D., et al. Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients. Clin. Infect. Dis. 2022;75:e822–e826. doi: 10.1093/cid/ciab1041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab1041</ArticleId><ArticleId IdType="pmc">PMC8754807</ArticleId><ArticleId IdType="pubmed">34915551</ArticleId></ArticleIdList></Reference><Reference><Citation>Saciuk Y., Kertes J., Shamir Stein N., Ekka Zohar A. Effectiveness of a Third Dose of BNT162b2 mRNA Vaccine. J. Infect. Dis. 2022;225:30–33. doi: 10.1093/infdis/jiab556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab556</ArticleId><ArticleId IdType="pmc">PMC8689889</ArticleId><ArticleId IdType="pubmed">34726239</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Beltran W.F., St Denis K.J., Hoelzemer A., Lam E.C., Nitido A.D., Sheehan M.L., Berrios C., Ofoman O., Chang C.C., Hauser B.M., et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell. 2022;185:457–466.e454. doi: 10.1016/j.cell.2021.12.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.12.033</ArticleId><ArticleId IdType="pmc">PMC8733787</ArticleId><ArticleId IdType="pubmed">34995482</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon C.J., Tchesnokov E.P., Woolner E., Perry J.K., Feng J.Y., Porter D.P., Götte M. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J. Biol. Chem. 2020;295:6785–6797. doi: 10.1074/jbc.RA120.013679.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA120.013679</ArticleId><ArticleId IdType="pmc">PMC7242698</ArticleId><ArticleId IdType="pubmed">32284326</ArticleId></ArticleIdList></Reference><Reference><Citation>Gbinigie O., Ogburn E., Allen J., Dorward J., Dobson M., Madden T.A., Yu L.M., Lowe D.M., Rahman N., Petrou S., et al. Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): Protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease. BMJ Open. 2023;13:e069176. doi: 10.1136/bmjopen-2022-069176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2022-069176</ArticleId><ArticleId IdType="pmc">PMC10407406</ArticleId><ArticleId IdType="pubmed">37550022</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon C.J., Tchesnokov E.P., Feng J.Y., Porter D.P., Götte M. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J. Biol. Chem. 2020;295:4773–4779. doi: 10.1074/jbc.AC120.013056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.AC120.013056</ArticleId><ArticleId IdType="pmc">PMC7152756</ArticleId><ArticleId IdType="pubmed">32094225</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabinger F., Stiller C., Schmitzová J., Dienemann C., Kokic G., Hillen H.S., Höbartner C., Cramer P. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat. Struct. Mol. Biol. 2021;28:740–746. doi: 10.1038/s41594-021-00651-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41594-021-00651-0</ArticleId><ArticleId IdType="pmc">PMC8437801</ArticleId><ArticleId IdType="pubmed">34381216</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler C.C., Hobbs F.D.R., Gbinigie O.A., Rahman N.M., Hayward G., Richards D.B., Dorward J., Lowe D.M., Standing J.F., Breuer J., et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): An open-label, platform-adaptive randomised controlled trial. Lancet. 2023;401:281–293. doi: 10.1016/S0140-6736(22)02597-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)02597-1</ArticleId><ArticleId IdType="pmc">PMC9779781</ArticleId><ArticleId IdType="pubmed">36566761</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoo S.H., FitzGerald R., Saunders G., Middleton C., Ahmad S., Edwards C.J., Hadjiyiannakis D., Walker L., Lyon R., Shaw V., et al. Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): A randomised, placebo-controlled, double-blind, phase 2 trial. Lancet. Infect. Dis. 2023;23:183–195. doi: 10.1016/S1473-3099(22)00644-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00644-2</ArticleId><ArticleId IdType="pmc">PMC9662684</ArticleId><ArticleId IdType="pubmed">36272432</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelnabi R., Foo C.S., Kaptein S.J.F., Zhang X., Do T.N.D., Langendries L., Vangeel L., Breuer J., Pang J., Williams R., et al. The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model. EBioMedicine. 2021;72:103595. doi: 10.1016/j.ebiom.2021.103595.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103595</ArticleId><ArticleId IdType="pmc">PMC8461366</ArticleId><ArticleId IdType="pubmed">34571361</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J.-L., Li Y.-H., Wang L.-L., Liu H.-Q., Lu S.-Y., Liu Y., Li K., Liu B., Li S.-Y., Shao F.-M., et al. Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients. Signal Transduct. Target. Ther. 2021;6:414. doi: 10.1038/s41392-021-00835-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00835-6</ArticleId><ArticleId IdType="pmc">PMC8646019</ArticleId><ArticleId IdType="pubmed">34873151</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H., Wang Z., Jiang C., Zhang Y., Zhang Y., Xu M., Zhang Y., Wang Y., Liu X., An Z., et al. Oral azvudine for mild-to-moderate COVID-19 in high risk, nonhospitalized adults: Results of a real-world study. J. Med. Virol. 2023;95:e28947. doi: 10.1002/jmv.28947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28947</ArticleId><ArticleId IdType="pubmed">37470209</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng W., Guo S., Cao S., Shuda M., Robinson-McCarthy L.R., McCarthy K.R., Shuda Y., Paniz Mondolfi A.E., Bryce C., Grimes Z., et al. Development and characterization of a new monoclonal antibody against SARS-CoV-2 NSP12 (RdRp) J. Med. Virol. 2023;95:e28246. doi: 10.1002/jmv.28246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28246</ArticleId><ArticleId IdType="pmc">PMC9874566</ArticleId><ArticleId IdType="pubmed">36271490</ArticleId></ArticleIdList></Reference><Reference><Citation>He S.-t., Qin H., Guan L., Liu K., Hong B., Zhang X., Lou F., Li M., Lin W., Chen Y., et al. Bovine lactoferrin inhibits SARS-CoV-2 and SARS-CoV-1 by targeting the RdRp complex and alleviates viral infection in the hamster model. J. Med. Virol. 2023;95:e28281. doi: 10.1002/jmv.28281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28281</ArticleId><ArticleId IdType="pmc">PMC9878033</ArticleId><ArticleId IdType="pubmed">36329614</ArticleId></ArticleIdList></Reference><Reference><Citation>Minetti C.A., Remeta D.P., Hashimoto K., Bonala R., Chennamshetti R., Yin X., Garcia-Diaz M., Grollman A.P., Johnson F., Sidorenko V.S. Characterization of Aurintricarboxylic Acid (ATA) Interactions with Plasma Transporter Protein and SARS-CoV-2 Viral Targets: Correlation of Functional Activity and Binding Energetics. Life. 2022;12:872. doi: 10.3390/life12060872.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life12060872</ArticleId><ArticleId IdType="pmc">PMC9227171</ArticleId><ArticleId IdType="pubmed">35743905</ArticleId></ArticleIdList></Reference><Reference><Citation>Prajapati K.S., Singh A.K., Kushwaha P.P., Shuaib M., Maurya S.K., Gupta S., Senapati S., Singh S.P., Waseem M., Kumar S. Withaniasomnifera phytochemicals possess SARS-CoV-2 RdRp and human TMPRSS2 protein binding potential. Vegetos. 2023;36:701–720. doi: 10.1007/s42535-022-00404-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s42535-022-00404-4</ArticleId><ArticleId IdType="pmc">PMC9199469</ArticleId><ArticleId IdType="pubmed">35729946</ArticleId></ArticleIdList></Reference><Reference><Citation>David A.B., Diamant E., Dor E., Barnea A., Natan N., Levin L., Chapman S., Mimran L.C., Epstein E., Zichel R., et al. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries. Molecules. 2021;26:3213. doi: 10.3390/molecules26113213.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules26113213</ArticleId><ArticleId IdType="pmc">PMC8198929</ArticleId><ArticleId IdType="pubmed">34072087</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond J., Leister-Tebbe H., Gardner A., Abreu P., Bao W., Wisemandle W., Baniecki M., Hendrick V.M., Damle B., Simón-Campos A., et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N. Engl. J. Med. 2022;386:1397–1408. doi: 10.1056/NEJMoa2118542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118542</ArticleId><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Pan X., Zhang S., Li M., Ma K., Fan C., Lv Y., Guan X., Yang Y., Ye X., et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: A multicenter randomized controlled study. Lancet Reg. Health. West. Pac. 2023;33:100694. doi: 10.1016/j.lanwpc.2023.100694.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanwpc.2023.100694</ArticleId><ArticleId IdType="pmc">PMC9899586</ArticleId><ArticleId IdType="pubmed">36777445</ArticleId></ArticleIdList></Reference><Reference><Citation>Unoh Y., Uehara S., Nakahara K., Nobori H., Yamatsu Y., Yamamoto S., Maruyama Y., Taoda Y., Kasamatsu K., Suto T., et al. Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19. J. Med. Chem. 2022;65:6499–6512. doi: 10.1021/acs.jmedchem.2c00117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.2c00117</ArticleId><ArticleId IdType="pmc">PMC8982737</ArticleId><ArticleId IdType="pubmed">35352927</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukae H., Yotsuyanagi H., Ohmagari N., Doi Y., Sakaguchi H., Sonoyama T., Ichihashi G., Sanaki T., Baba K., Tsuge Y., et al. Efficacy and Safety of Ensitrelvir in Patients with Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study. Clin. Infect. Dis. 2023;76:1403–1411. doi: 10.1093/cid/ciac933.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac933</ArticleId><ArticleId IdType="pmc">PMC10110269</ArticleId><ArticleId IdType="pubmed">36477182</ArticleId></ArticleIdList></Reference><Reference><Citation>Balakrishnan A., Reyes A., Shen R., Bisht N., Sweeney J., Levene R., McAllister N., Cressey T., Manalo N., Rhodin M.H., et al. Molecular Basis for Antiviral Action of EDP-235: A Potent and Selective SARS-CoV-2 3CLpro Inhibitor for the Treatment of Covid 19. FASEB J. 2022;36 doi: 10.1096/fasebj.2022.36.S1.0R514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fasebj.2022.36.S1.0R514</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A., Schulz L., Widera M., Mehdipour A.R., Tascher G., et al. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature. 2020;587:657–662. doi: 10.1038/s41586-020-2601-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2601-5</ArticleId><ArticleId IdType="pmc">PMC7116779</ArticleId><ArticleId IdType="pubmed">32726803</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan S., Gao X., Tang K., Cai J.P., Hu M., Luo P., Wen L., Ye Z.W., Luo C., Tsang J.O., et al. Targeting papain-like protease for broad-spectrum coronavirus inhibition. Protein Cell. 2022;13:940–953. doi: 10.1007/s13238-022-00909-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13238-022-00909-3</ArticleId><ArticleId IdType="pmc">PMC8983325</ArticleId><ArticleId IdType="pubmed">35384604</ArticleId></ArticleIdList></Reference><Reference><Citation>Napolitano V., Dabrowska A., Schorpp K., Mourão A., Barreto-Duran E., Benedyk M., Botwina P., Brandner S., Bostock M., Chykunova Y., et al. Acriflavine, a clinically approved drug, inhibits SARS-CoV-2 and other betacoronaviruses. Cell Chem. Biol. 2022;29:774–784.e778. doi: 10.1016/j.chembiol.2021.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chembiol.2021.11.006</ArticleId><ArticleId IdType="pmc">PMC8751734</ArticleId><ArticleId IdType="pubmed">35021060</ArticleId></ArticleIdList></Reference><Reference><Citation>Song S., Kwon O.S., Chung Y.B. Pharmacokinetics and metabolism of acriflavine in rats following intravenous or intramuscular administration of AG60, a mixture of acriflavine and guanosine, a potential antitumour agent. Xenobiotica. 2005;35:755–773. doi: 10.1080/00498250500188073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00498250500188073</ArticleId><ArticleId IdType="pubmed">16323364</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratia K., Pegan S., Takayama J., Sleeman K., Coughlin M., Baliji S., Chaudhuri R., Fu W., Prabhakar B.S., Johnson M.E., et al. A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc. Natl. Acad. Sci. USA. 2008;105:16119–16124. doi: 10.1073/pnas.0805240105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0805240105</ArticleId><ArticleId IdType="pmc">PMC2571001</ArticleId><ArticleId IdType="pubmed">18852458</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Z., Huang B., Tang J., Liu S., Liu M., Ye Y., Liu Z., Xiong Y., Zhu W., Cao D., et al. The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery. Nat. Commun. 2021;12:488. doi: 10.1038/s41467-020-20718-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-20718-8</ArticleId><ArticleId IdType="pmc">PMC7817691</ArticleId><ArticleId IdType="pubmed">33473130</ArticleId></ArticleIdList></Reference><Reference><Citation>Savarino A., Di Trani L., Donatelli I., Cauda R., Cassone A. New insights into the antiviral effects of chloroquine. Lancet Infect. Dis. 2006;6:67–69. doi: 10.1016/S1473-3099(06)70361-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(06)70361-9</ArticleId><ArticleId IdType="pmc">PMC7129107</ArticleId><ArticleId IdType="pubmed">16439323</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., Shi Z., Hu Z., Zhong W., Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–271. doi: 10.1038/s41422-020-0282-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-020-0282-0</ArticleId><ArticleId IdType="pmc">PMC7054408</ArticleId><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar J., Jain S., Meena J., Yadav A. Efficacy and safety of hydroxychloroquine/chloroquine against SARS-CoV-2 infection: A systematic review and meta-analysis. J. Infect. Chemother. 2021;27:882–889. doi: 10.1016/j.jiac.2021.02.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiac.2021.02.021</ArticleId><ArticleId IdType="pmc">PMC7899036</ArticleId><ArticleId IdType="pubmed">33678548</ArticleId></ArticleIdList></Reference><Reference><Citation>Llanos-Cuentas A., Schwalb A., Quintana J.L., Delfin B., Alvarez F., Ugarte-Gil C., Guerra Gronerth R.I., Lucchetti A., Grogl M., Gotuzzo E. Hydroxychloroquine to prevent SARS-CoV-2 infection among healthcare workers: Early termination of a phase 3, randomised, open-label, controlled clinical trial. BMC Res. Notes. 2023;16:22. doi: 10.1186/s13104-023-06281-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13104-023-06281-7</ArticleId><ArticleId IdType="pmc">PMC9970848</ArticleId><ArticleId IdType="pubmed">36849996</ArticleId></ArticleIdList></Reference><Reference><Citation>Brevini T., Maes M., Webb G.J., John B.V., Fuchs C.D., Buescher G., Wang L., Griffiths C., Brown M.L., Scott W.E., et al. FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. Nature. 2023;615:134–142. doi: 10.1038/s41586-022-05594-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05594-0</ArticleId><ArticleId IdType="pmc">PMC9977684</ArticleId><ArticleId IdType="pubmed">36470304</ArticleId></ArticleIdList></Reference><Reference><Citation>Monteil V., Kwon H., Prado P., Hagelkrüys A., Wimmer R.A., Stahl M., Leopoldi A., Garreta E., Hurtado Del Pozo C., Prosper F., et al. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. Cell. 2020;181:905–913.e907. doi: 10.1016/j.cell.2020.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.04.004</ArticleId><ArticleId IdType="pmc">PMC7181998</ArticleId><ArticleId IdType="pubmed">32333836</ArticleId></ArticleIdList></Reference><Reference><Citation>Karoyan P., Vieillard V., Gómez-Morales L., Odile E., Guihot A., Luyt C.E., Denis A., Grondin P., Lequin O. Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection. Commun. Biol. 2021;4:197. doi: 10.1038/s42003-021-01736-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-021-01736-8</ArticleId><ArticleId IdType="pmc">PMC7881012</ArticleId><ArticleId IdType="pubmed">33580154</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin Y.-H., Jeong K., Lee J., Lee H.J., Yim J., Kim J., Kim S., Park S.B. Inhibition of ACE2-Spike Interaction by an ACE2 Binder Suppresses SARS-CoV-2 Entry. Angew. Chem. Int. Ed. 2022;61:e202115695. doi: 10.1002/anie.202115695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.202115695</ArticleId><ArticleId IdType="pmc">PMC9011661</ArticleId><ArticleId IdType="pubmed">35043545</ArticleId></ArticleIdList></Reference><Reference><Citation>Essalmani R., Jain J., Susan-Resiga D., Andréo U., Evagelidis A., Derbali R.M., Huynh D.N., Dallaire F., Laporte M., Delpal A., et al. Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity. J. Virol. 2022;96:e0012822. doi: 10.1128/jvi.00128-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.00128-22</ArticleId><ArticleId IdType="pmc">PMC9044946</ArticleId><ArticleId IdType="pubmed">35343766</ArticleId></ArticleIdList></Reference><Reference><Citation>Bestle D., Heindl M.R., Limburg H., Van Lam van T., Pilgram O., Moulton H., Stein D.A., Hardes K., Eickmann M., Dolnik O., et al. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. Life Sci. Alliance. 2020;3:e202000786. doi: 10.26508/lsa.202000786.</Citation><ArticleIdList><ArticleId IdType="doi">10.26508/lsa.202000786</ArticleId><ArticleId IdType="pmc">PMC7383062</ArticleId><ArticleId IdType="pubmed">32703818</ArticleId></ArticleIdList></Reference><Reference><Citation>Pászti-Gere E., Szentkirályi-Tóth A., Szabó P., Steinmetzer T., Fliszár-Nyúl E., Poór M. In vitro characterization of the furin inhibitor MI-1851: Albumin binding, interaction with cytochrome P450 enzymes and cytotoxicity. Biomed. Pharmacother. 2022;151:113124. doi: 10.1016/j.biopha.2022.113124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2022.113124</ArticleId><ArticleId IdType="pmc">PMC9110138</ArticleId><ArticleId IdType="pubmed">35594709</ArticleId></ArticleIdList></Reference><Reference><Citation>Li K., Meyerholz D.K., Bartlett J.A., McCray P.B., Jr. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19. mBio. 2021;12:e0097021. doi: 10.1128/mBio.00970-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.00970-21</ArticleId><ArticleId IdType="pmc">PMC8406266</ArticleId><ArticleId IdType="pubmed">34340553</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinoshita T., Shinoda M., Nishizaki Y., Shiraki K., Hirai Y., Kichikawa Y., Tsushima K., Shinkai M., Komura N., Yoshida K., et al. A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study) BMC Med. 2022;20:342. doi: 10.1186/s12916-022-02518-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-022-02518-7</ArticleId><ArticleId IdType="pmc">PMC9512971</ArticleId><ArticleId IdType="pubmed">36163020</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunst J.D., Staerke N.B., Pahus M.H., Kristensen L.H., Bodilsen J., Lohse N., Dalgaard L.S., Brønnum D., Fröbert O., Hønge B., et al. Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial. EClinicalMedicine. 2021;35:100849. doi: 10.1016/j.eclinm.2021.100849.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.100849</ArticleId><ArticleId IdType="pmc">PMC8060682</ArticleId><ArticleId IdType="pubmed">33903855</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhuravel S.V., Khmelnitskiy O.K., Burlaka O.O., Gritsan A.I., Goloshchekin B.M., Kim S., Hong K.Y. Nafamostat in hospitalized patients with moderate to severe COVID-19 pneumonia: A randomised Phase II clinical trial. EClinicalMedicine. 2021;41:101169. doi: 10.1016/j.eclinm.2021.101169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101169</ArticleId><ArticleId IdType="pmc">PMC8548051</ArticleId><ArticleId IdType="pubmed">34723164</ArticleId></ArticleIdList></Reference><Reference><Citation>Shapira T., Monreal I.A., Dion S.P., Buchholz D.W., Imbiakha B., Olmstead A.D., Jager M., Désilets A., Gao G., Martins M., et al. A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic. Nature. 2022;605:340–348. doi: 10.1038/s41586-022-04661-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04661-w</ArticleId><ArticleId IdType="pmc">PMC9095466</ArticleId><ArticleId IdType="pubmed">35344983</ArticleId></ArticleIdList></Reference><Reference><Citation>Moumbock A.F.A., Tran H.T.T., Lamy E., Günther S. BC-11 is a covalent TMPRSS2 fragment inhibitor that impedes SARS-CoV-2 host cell entry. Arch. Der Pharm. 2023;356:2200371. doi: 10.1002/ardp.202200371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ardp.202200371</ArticleId><ArticleId IdType="pmc">PMC9874818</ArticleId><ArticleId IdType="pubmed">36316225</ArticleId></ArticleIdList></Reference><Reference><Citation>Padmanabhan P., Dixit N.M. Modelling how increased Cathepsin B/L and decreased TMPRSS2 usage for cell entry by the SARS-CoV-2 Omicron variant may affect the efficacy and synergy of TMPRSS2 and Cathepsin B/L inhibitors. J. Theor. Biol. 2023;572:111568. doi: 10.1016/j.jtbi.2023.111568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtbi.2023.111568</ArticleId><ArticleId IdType="pubmed">37393986</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou N., Pan T., Zhang J., Li Q., Zhang X., Bai C., Huang F., Peng T., Zhang J., Liu C., et al. Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) J. Biol. Chem. 2016;291:9218–9232. doi: 10.1074/jbc.M116.716100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M116.716100</ArticleId><ArticleId IdType="pmc">PMC4861487</ArticleId><ArticleId IdType="pubmed">26953343</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu F., Pan T., Huang F., Ying R., Liu J., Fan H., Zhang J., Liu W., Lin Y., Yuan Y., et al. Glycopeptide Antibiotic Teicoplanin Inhibits Cell Entry of SARS-CoV-2 by Suppressing the Proteolytic Activity of Cathepsin L. Front. Microbiol. 2022;13:884034. doi: 10.3389/fmicb.2022.884034.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2022.884034</ArticleId><ArticleId IdType="pmc">PMC9096618</ArticleId><ArticleId IdType="pubmed">35572668</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S., Liu L., Wang C., Wang Z., Duan X., Chen G., Zhou H., Shao H. Establishment of a pseudovirus neutralization assay based on SARS-CoV-2 S protein incorporated into lentiviral particles. Biosaf. Health. 2022;4:38–44. doi: 10.1016/j.bsheal.2021.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bsheal.2021.12.006</ArticleId><ArticleId IdType="pmc">PMC8721934</ArticleId><ArticleId IdType="pubmed">35005601</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma X.R., Alugubelli Y.R., Ma Y., Vatansever E.C., Scott D.A., Qiao Y., Yu G., Xu S., Liu W.R. MPI8 is Potent against SARS-CoV-2 by Inhibiting Dually and Selectively the SARS-CoV-2 Main Protease and the Host Cathepsin L. ChemMedChem. 2022;17:e202100456. doi: 10.1002/cmdc.202100456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cmdc.202100456</ArticleId><ArticleId IdType="pmc">PMC8427127</ArticleId><ArticleId IdType="pubmed">34242492</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodon J., Muñoz-Basagoiti J., Perez-Zsolt D., Noguera-Julian M., Paredes R., Mateu L., Quiñones C., Perez C., Erkizia I., Blanco I., et al. Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen. Front. Pharmacol. 2021;12:646676. doi: 10.3389/fphar.2021.646676.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.646676</ArticleId><ArticleId IdType="pmc">PMC8033486</ArticleId><ArticleId IdType="pubmed">33841165</ArticleId></ArticleIdList></Reference><Reference><Citation>Costanzi E., Kuzikov M., Esposito F., Albani S., Demitri N., Giabbai B., Camasta M., Tramontano E., Rossetti G., Zaliani A., et al. Structural and Biochemical Analysis of the Dual Inhibition of MG-132 against SARS-CoV-2 Main Protease (Mpro/3CLpro) and Human Cathepsin-L. Int. J. Mol. Sci. 2021;22:11779. doi: 10.3390/ijms222111779.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms222111779</ArticleId><ArticleId IdType="pmc">PMC8583849</ArticleId><ArticleId IdType="pubmed">34769210</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar P., Mathayan M., Smieszek S.P., Przychodzen B.P., Koprivica V., Birznieks G., Polymeropoulos M.H., Prabhakar B.S. Identification of potential COVID-19 treatment compounds which inhibit SARS Cov2 prototypic, Delta and Omicron variant infection. Virology. 2022;572:64–71. doi: 10.1016/j.virol.2022.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2022.05.004</ArticleId><ArticleId IdType="pmc">PMC9108900</ArticleId><ArticleId IdType="pubmed">35598394</ArticleId></ArticleIdList></Reference><Reference><Citation>McIlwain D.R., Berger T., Mak T.W. Caspase functions in cell death and disease. Cold Spring Harb. Perspect. Biol. 2013;5:a008656. doi: 10.1101/cshperspect.a008656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a008656</ArticleId><ArticleId IdType="pmc">PMC3683896</ArticleId><ArticleId IdType="pubmed">23545416</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu H., Hou Y., Yang D., Wen L., Shuai H., Yoon C., Shi J., Chai Y., Yuen T.T.-T., Hu B., et al. Coronaviruses exploit a host cysteine-aspartic protease for replication. Nature. 2022;609:785–792. doi: 10.1038/s41586-022-05148-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05148-4</ArticleId><ArticleId IdType="pubmed">35922005</ArticleId></ArticleIdList></Reference><Reference><Citation>Samelson A.J., Tran Q.D., Robinot R., Carrau L., Rezelj V.V., Kain A.M., Chen M., Ramadoss G.N., Guo X., Lim S.A., et al. BRD2 inhibition blocks SARS-CoV-2 infection by reducing transcription of the host cell receptor ACE2. Nat. Cell Biol. 2022;24:24–34. doi: 10.1038/s41556-021-00821-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41556-021-00821-8</ArticleId><ArticleId IdType="pmc">PMC8820466</ArticleId><ArticleId IdType="pubmed">35027731</ArticleId></ArticleIdList></Reference><Reference><Citation>Braga L., Ali H., Secco I., Chiavacci E., Neves G., Goldhill D., Penn R., Jimenez-Guardeño J.M., Ortega-Prieto A.M., Bussani R., et al. Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia. Nature. 2021;594:88–93. doi: 10.1038/s41586-021-03491-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03491-6</ArticleId><ArticleId IdType="pmc">PMC7611055</ArticleId><ArticleId IdType="pubmed">33827113</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., Verma A., Garcia G., Jr., Ramage H., Lucas A., Myers R.L., Michaelson J.J., Coryell W., Kumar A., Charney A.W., et al. Targeting the coronavirus nucleocapsid protein through GSK-3 inhibition. Proc. Natl. Acad. Sci. USA. 2021;118:e2113401118. doi: 10.1073/pnas.2113401118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2113401118</ArticleId><ArticleId IdType="pmc">PMC8594528</ArticleId><ArticleId IdType="pubmed">34593624</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin M.J., Ustianowski A., De Wit S., Launay O., Avila M., Templeton A., Yuan Y., Seegobin S., Ellery A., Levinson D.J., et al. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19. N. Engl. J. Med. 2022;386:2188–2200. doi: 10.1056/NEJMoa2116620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116620</ArticleId><ArticleId IdType="pmc">PMC9069994</ArticleId><ArticleId IdType="pubmed">35443106</ArticleId></ArticleIdList></Reference><Reference><Citation>Loo Y.M., McTamney P.M., Arends R.H., Abram M.E., Aksyuk A.A., Diallo S., Flores D.J., Kelly E.J., Ren K., Roque R., et al. The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans. Sci. Transl. Med. 2022;14:eabl8124. doi: 10.1126/scitranslmed.abl8124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abl8124</ArticleId><ArticleId IdType="pmc">PMC8939769</ArticleId><ArticleId IdType="pubmed">35076282</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruel T., Hadjadj J., Maes P., Planas D., Seve A., Staropoli I., Guivel-Benhassine F., Porrot F., Bolland W.H., Nguyen Y., et al. Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. Nat. Med. 2022;28:1297–1302. doi: 10.1038/s41591-022-01792-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01792-5</ArticleId><ArticleId IdType="pubmed">35322239</ArticleId></ArticleIdList></Reference><Reference><Citation>Case J.B., Mackin S., Errico J.M., Chong Z., Madden E.A., Whitener B., Guarino B., Schmid M.A., Rosenthal K., Ren K., et al. Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains. Nat. Commun. 2022;13:3824. doi: 10.1038/s41467-022-31615-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-31615-7</ArticleId><ArticleId IdType="pmc">PMC9250508</ArticleId><ArticleId IdType="pubmed">35780162</ArticleId></ArticleIdList></Reference><Reference><Citation>Biosciences B. Brii Bio Announces Amubarvimab/Romlusevimab Combination Retains Neutralizing Activity against Omicron SARS-CoV-2 Variant.  [(accessed on 12 December 2021)].  Available online:  https://www.briibio.com/en/media/press-release/</Citation></Reference><Reference><Citation>Wang R., Zhang Q., Zhang R., Aw Z.Q., Chen P., Wong Y.H., Hong J., Ju B., Shi X., Ding Q., et al. SARS-CoV-2 Omicron Variants Reduce Antibody Neutralization and Acquire Usage of Mouse ACE2. Front. Immunol. 2022;13:854952. doi: 10.3389/fimmu.2022.854952.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.854952</ArticleId><ArticleId IdType="pmc">PMC9247160</ArticleId><ArticleId IdType="pubmed">35784344</ArticleId></ArticleIdList></Reference><Reference><Citation>Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): A randomised controlled trial. Lancet Infect. Dis. 2022;22:622–635. doi: 10.1016/S1473-3099(21)00751-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00751-9</ArticleId><ArticleId IdType="pmc">PMC8700279</ArticleId><ArticleId IdType="pubmed">34953520</ArticleId></ArticleIdList></Reference><Reference><Citation>Westendorf K., Žentelis S., Wang L., Foster D., Vaillancourt P., Wiggin M., Lovett E., van der Lee R., Hendle J., Pustilnik A., et al. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Cell Rep. 2022;39:110812. doi: 10.1016/j.celrep.2022.110812.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.110812</ArticleId><ArticleId IdType="pmc">PMC9035363</ArticleId><ArticleId IdType="pubmed">35568025</ArticleId></ArticleIdList></Reference><Reference><Citation>Iketani S., Liu L., Guo Y., Liu L., Chan J.F.W., Huang Y., Wang M., Luo Y., Yu J., Chu H., et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature. 2022;604:553–556. doi: 10.1038/s41586-022-04594-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04594-4</ArticleId><ArticleId IdType="pmc">PMC9021018</ArticleId><ArticleId IdType="pubmed">35240676</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L., Wang P., Nair M.S., Yu J., Rapp M., Wang Q., Luo Y., Chan J.F., Sahi V., Figueroa A., et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature. 2020;584:450–456. doi: 10.1038/s41586-020-2571-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2571-7</ArticleId><ArticleId IdType="pubmed">32698192</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi X., Yan R., Zhang J., Zhang G., Zhang Y., Hao M., Zhang Z., Fan P., Dong Y., Yang Y., et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science. 2020;369:650–655. doi: 10.1126/science.abc6952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc6952</ArticleId><ArticleId IdType="pmc">PMC7319273</ArticleId><ArticleId IdType="pubmed">32571838</ArticleId></ArticleIdList></Reference><Reference><Citation>McCallum M., De Marco A., Lempp F.A., Tortorici M.A., Pinto D., Walls A.C., Beltramello M., Chen A., Liu Z., Zatta F., et al. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell. 2021;184:2332–2347.e2316. doi: 10.1016/j.cell.2021.03.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.03.028</ArticleId><ArticleId IdType="pmc">PMC7962585</ArticleId><ArticleId IdType="pubmed">33761326</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W., Wang F., Li Y., Yan L., Liu L., Zhu W., Ma P., Shi X., Yang G. Potent NTD-Targeting Neutralizing Antibodies against SARS-CoV-2 Selected from a Synthetic Immune System. Vaccines. 2023;11:771. doi: 10.3390/vaccines11040771.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11040771</ArticleId><ArticleId IdType="pmc">PMC10143083</ArticleId><ArticleId IdType="pubmed">37112683</ArticleId></ArticleIdList></Reference><Reference><Citation>Montgomerie I., Bird T.W., Palmer O.R., Mason N.C., Pankhurst T.E., Lawley B., Hernández L.C., Harfoot R., Authier-Hall A., Anderson D.E., et al. Incorporation of SARS-CoV-2 spike NTD to RBD protein vaccine improves immunity against viral variants. iScience. 2023;26:106256. doi: 10.1016/j.isci.2023.106256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2023.106256</ArticleId><ArticleId IdType="pmc">PMC9940465</ArticleId><ArticleId IdType="pubmed">36845030</ArticleId></ArticleIdList></Reference><Reference><Citation>Haslwanter D., Dieterle M.E., Wec A.Z., O’Brien C.M., Sakharkar M., Florez C., Tong K., Rappazzo C.G., Lasso G., Vergnolle O., et al. A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants. mBio. 2021;12:e0247321. doi: 10.1128/mBio.02473-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.02473-21</ArticleId><ArticleId IdType="pmc">PMC8546647</ArticleId><ArticleId IdType="pubmed">34607456</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox M., Peacock T.P., Harvey W.T., Hughes J., Wright D.W., Willett B.J., Thomson E., Gupta R.K., Peacock S.J., Robertson D.L., et al. SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies. Nat. Rev. Microbiol. 2023;21:112–124. doi: 10.1038/s41579-022-00809-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00809-7</ArticleId><ArticleId IdType="pmc">PMC9616429</ArticleId><ArticleId IdType="pubmed">36307535</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccoli L., Park Y.J., Tortorici M.A., Czudnochowski N., Walls A.C., Beltramello M., Silacci-Fregni C., Pinto D., Rosen L.E., Bowen J.E., et al. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. Cell. 2020;183:1024–1042.e1021. doi: 10.1016/j.cell.2020.09.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.037</ArticleId><ArticleId IdType="pmc">PMC7494283</ArticleId><ArticleId IdType="pubmed">32991844</ArticleId></ArticleIdList></Reference><Reference><Citation>Dacon C., Tucker C., Peng L., Lee C.D., Lin T.H., Yuan M., Cong Y., Wang L., Purser L., Williams J.K., et al. Broadly neutralizing antibodies target the coronavirus fusion peptide. Science. 2022;377:728–735. doi: 10.1126/science.abq3773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abq3773</ArticleId><ArticleId IdType="pmc">PMC9348754</ArticleId><ArticleId IdType="pubmed">35857439</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia S., Zhu Y., Liu M., Lan Q., Xu W., Wu Y., Ying T., Liu S., Shi Z., Jiang S., et al. Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell. Mol. Immunol. 2020;17:765–767. doi: 10.1038/s41423-020-0374-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-0374-2</ArticleId><ArticleId IdType="pmc">PMC7075278</ArticleId><ArticleId IdType="pubmed">32047258</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia S., Chan J.F., Wang L., Jiao F., Chik K.K., Chu H., Lan Q., Xu W., Wang Q., Wang C., et al. Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant. Cell Res. 2022;32:404–406. doi: 10.1038/s41422-022-00617-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-022-00617-x</ArticleId><ArticleId IdType="pmc">PMC8793821</ArticleId><ArticleId IdType="pubmed">35087243</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz K.S., Geers D., Vries R.D.d., Bovier T.F., Mykytyn A.Z., Kessel C.H.G.v., Haagmans B.L., Porotto M., Swart R.L.d., Moscona A. Potency of Fusion-Inhibitory Lipopeptides against SARS-CoV-2 Variants of Concern. mBio. 2022;13:e01249-01222. doi: 10.1128/mbio.01249-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mbio.01249-22</ArticleId><ArticleId IdType="pmc">PMC9239157</ArticleId><ArticleId IdType="pubmed">35695453</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>